title: Deliverability of the Resolute Integrity stent and a post hoc comparison of radial and femoral access: the DELIVER study.
abstract: OBJECTIVE
  DELIVER (DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER stenting) was a prospective, multicenter, all-comers registry to assess the deliverability of the Resolute Integrity™ zotarolimus-eluting stent (R-ZES).
  
  
  METHODS
  Patients (n=7740 patients, 10449 lesions) undergoing percutaneous coronary intervention and deemed suitable for R-ZES implantation were enrolled and treated according to standard practice of the participating centers in 30 countries. Outcomes included delivery success and in-hospital target lesion failure (TLF), major adverse cardiac event (MACE), and Academic Research Consortium definite/probable stent thrombosis. We performed a post hoc analysis comparing deliverability, in-hospital clinical outcomes and resource utilization with radial vs. femoral access.
  
  
  RESULTS
  A high proportion of the population had complex disease (71%): mean lesion length was 26.7±17.5 mm, 35% of lesions were moderately/severely calcified and 17% were bifurcated. Femoral and radial accesses were used in 53% and 46% of patients, respectively. Patients treated using femoral access had more complex coronary artery disease. Primary delivery success was 98.9% and did not differ by approach. Radial access was associated with lower stent and balloon utilization, but higher guide catheter utilization, lower procedure duration, and contrast administered compared with femoral access. In-hospital TLF and MACE occurred in 1.6% of patients; definite or probable stent thrombosis occurred in 0.2%. Clinical outcomes did not differ by vascular access.
  
  
  CONCLUSIONS
  R-ZES was found to be highly deliverable in a complex, all-comers, international population, regardless of whether radial or femoral access was used. In-hospital outcomes were excellent with very low risk of complications.
authors.affiliation: Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands. Electronic address: j.polad@jbz.nl.
authors.forename: Jawed
authors.initials: J
authors.lastname: Polad
authors.affiliation: University of Ulm, Ulm, Germany.
authors.forename: Jochen
authors.initials: J
authors.lastname: Wöhrle
authors.affiliation: Medanta, Gurgaon, India.
authors.forename: Balbir
authors.initials: B
authors.lastname: Singh
authors.affiliation: Care Institute of Medical Sciences, Ahmedabad, India.
authors.forename: Milan
authors.initials: M
authors.lastname: Chag
authors.affiliation: Korea University Guro Hospital, Seoul, Republic of Korea.
authors.forename: Seung-Woon
authors.initials: SW
authors.lastname: Rha
authors.affiliation: National Heart Foundation Hospital and Research Institute, Dhaka, Bangladesh.
authors.forename: Fazila-Tun-Nesa
authors.initials: FT
authors.lastname: Malik
authors.affiliation: Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands.
authors.forename: Martijn
authors.initials: M
authors.lastname: van Eck
authors.affiliation: University of Ulm, Ulm, Germany. Electronic address: wolfgang.rottbauer@uniklinik-ulm.de.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Rottbauer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011446:Prospective Studies; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; C489443:zotarolimus; D020123:Sirolimus
keywords: Deliverability; Radial access; Resolute Integrity; Zotarolimus-eluting stent